Premium content from Motley Fool Hidden Winners UK
Our monthly Best Buys Now are designed to highlight our teamâs three favourite, most timely Buys from our growing list of small-cap recommendations, to help Fools build out their stock portfolios.
“Best Buys Now” Pick #1:
Ergomed (LSE:ERGO)
Why we like it: âInvesting in the pharmaceutical industry has obvious attractions. Healthcare spending remains relatively robust â even during economic downturns â as people always need to see their doctors and take their treatments. Yet investing in the companies making the drugs many of us take can be a very hit-or-miss situation, even if youâre a PhD or MD. This is why we at Hidden Winners have instead long been attracted to the companies providing these pharma makers with the instruments, lab equipment, and support services that they need. Ergomed (LSE: ERGO) is very much in that vein.
âThe company provides two main services for its clients. The first is PrimeVigilance, which assists customers (drug-makers) in their pharmacovigilance efforts (the process undertaken during and after drug trials to monitor clinical subjects for adverse events that may or may not be connected to the drug in question). The other division operates under the Ergomed brand and runs clinical research services. Both these services play into a wider trend in the pharmaceutical industry, that of outsourcing non-core tasks to specialist providers. The company ticks a lot of our boxes, being founder-led, in a fairly defensive and growing industry, with its shares trading at what could be an attractive valuation.â
Why we like it now: The recent full-year trading update from Ergomed showed the company recorded another positive year in 2022. Revenue was up 14.5% in constant currency terms to £145.3m (22.5% growth at actual exchange rates) with adjusted EBITDA expected to be in line with consensus estimates of circa £28m. There’s no certainty in life, but with its order books bulging at £295m at year-end and pharmaceutical firms keen to continue investing in drug development in the areas Ergomed focuses on, the short-term outlook for the group looks pretty good to us. Plus with net cash of £19.1m at the end of December, internal cash generation, and undrawn lending facilities of £80m, there is plenty of firepower to continue making bolt-on acquisitions and internal investments no matter the economic cycle. Ergomed isn’t cheap at 30x consensus 2022 earnings, but for a founder-led business catering to fairly defensive markets with a proven ability to provide growth in sales, profits, and actual cash flow, that doesn’t appear to be a ridiculous valuation.
“Best Buys Now” Pick #2:
Redacted
Want All 3 âBest Buys Nowâ Picks? Enter Your Email Address!
I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.
The post Just released: the 3 best small-cap stocks to buy now [PREMIUM PICKS] appeared first on The Motley Fool UK.
Should you invest £1,000 in Ergomed Plc right now?
When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.
And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Ergomed Plc made the list?
See the 6 stocks
setButtonColorDefaults(“#5FA85D”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43A24A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#FFFFFF”, ‘color’, ‘#FFFFFF’);
})()
More reading
Here’s what Stocks and Shares ISA millionaires are buying in 2023
2 dirt-cheap dividend shares Iâd buy for long-term passive income
A FTSE 100 dividend share Iâd buy for long-term passive income!
Record-breaking FTSE 100 still looks cheap. It hasnât peaked
When dividend investing goes badly wrong!
The Motley Fool UK has recommended Ergomed. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.